ReviewDrugs2006
Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials.The Journal of international medical research · 2020Pooled it
- Physicians' attitudes toward beta-blockers for the treatment of hypertension in Italy, Poland, and Turkey.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Development of Oral Tablets of Nebivolol with Improved Dissolution Properties, Based on Its Combinations with Cyclodextrins.Pharmaceutics · 2024Article
- Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?Current atherosclerosis reports · 2022Review
- Comparison of tablet splitting techniques for dosing accuracy of nebivolol tablets: Hand splitting versus tablet cutter and knife.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- A Novel function of Nebivolol: Stimulation of Adipose-derived Stem Cell Proliferation and Inhibition of Differentiation.Journal of stem cells & regenerative medicine · 2020Article
- Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.Journal of human hypertension · 2017Review
- Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol.Heart Asia · 2016Article
- Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers.Clujul medical (1957) · 2015Article
- Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.Clinical interventions in aging · 2010Review
- Article
- Nebivolol (bystolic), a novel Beta blocker for hypertension.P & T : a peer-reviewed journal for formulary management · 2009Article
- Stability Indicating RP-HPLC Estimation of Nebivolol Hydrochloride in Pharmaceutical Formulations.Indian journal of pharmaceutical sciences · 2008Article
- Nebivolol/Hydrochlorothiazide : a new fixed-dose combination for effective simplified antihypertensive therapy.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2008Article
- Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.Drugs · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nebivolol is a third-generation beta-adrenoceptor antagonist. It differs from other beta-adrenoceptor antagonists as it combines highly selective beta(1)-adrenoceptor antagonist properties with nitric oxide-mediated vasodilatory actions and beneficial effects on endothelial function. Nebivolol is approved in Europe and several other countries for the treatment of essential hypertension and in Europe for the treatment of stable mild or moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients aged >or=70 years. Nebivolol is an effective antihypertensive agent and is well tolerated in patients with hypertension. The drug also effectively decreased the composite endpoint of mortality and cardiovascular hospital admission in elderly patients with CHF and was generally well tolerated in this population. Nebivolol should be considered as an alternative first-line treatment option for patients with uncomplicated mild to moderate essential hypertension and in elderly patients with CHF.
Indexed as
Identifiers
16903772What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.